Mississippi judge denies drug maker’s and PhRMA’s request for preliminary injunction in 340B case
![court-900x400](/https/www.aha.org/sites/default/files/styles/900x400/public/2018-01/court-900x400.png?itok=s8D2_ej1)
A Mississippi judge July 1 denied Novartis Pharmaceuticals’ and PhRMA’s request for a preliminary injunction against enforcement of state law protecting 340B pricing for contract pharmacy arrangements. The AHA, along with 340B Health, the Mississippi Hospital Association and the Rural Hospital Alliance last month filed an amicus brief in the U.S. District Court for the Southern District of Mississippi defending the state's law.
Related News Articles
Headline
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending…
Headline
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…
Headline
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the…
Headline
Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products,…
Headline
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission’s 2024-2025 cycle. The AHA urged MedPAC to carefully…
Headline
The AHA July 26 submitted a letter expressing concerns in response to the recently introduced 340B Affording Care for Communities and Ensuring a Strong Safety-…